RCT: For adults with HIV, a 4-days-on and 3-days-off treatment strategy is noninferior to standard treatment for maintaining viral suppression.
11 Apr, 2022 | 01:56h | UTCA 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)
Commentary: Intermittent Treatment Strategy Is Effective for HIV – Consultant360
Commentaries on Twitter
New: A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial by Roland Landman and colleagues https://t.co/Tc2Rbo1ISt pic.twitter.com/YTV3XwfELo
— The Lancet HIV (@TheLancetHIV) February 3, 2022
In virologically suppressed people with HIV, randomization to intermittent ART (4 days on, 3 off) was non-inf. to daily dosing. Challenges what I thought about level of adherence needed. Is good adherence only needed during the viremic phase? https://t.co/lM8QZW0C9h
— David Serota (@serotavirus) March 16, 2022